Reuters logo
BRIEF-Hubei Biocause Pharma's insurance unit posts premium income, to sell shares in Tianjin firm
January 10, 2017 / 8:59 AM / 8 months ago

BRIEF-Hubei Biocause Pharma's insurance unit posts premium income, to sell shares in Tianjin firm

Jan 10 (Reuters) - Hubei Biocause Pharmaceutical Co Ltd

* Says its life insurance unit’s 2016 premium income at 26.6 billion yuan ($3.84 billion)

* Says life insurance unit plans to sell up to 419.0 million shares in Tianjin Tianhai Investment, representing 14.45 percent total issued share capital, in next 24 months

Source text in Chinese: bit.ly/2idFH2n; bit.ly/2izgrkW

Further company coverage: ($1 = 6.9222 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below